Pharmacoepidemiological survey of schizophrenia in Central India

Sonali B. Rode, Harsh V. Salankar, Pravin R. Verma, Umesh Sinha, Rajesh K. Ajagallay


Background:Schizophrenia is a chronic and debilitating psychiatric illness affecting around 0.3-0.7% of people at some point in their life. The rate of schizophrenia and related disorders is affected by some environmental factors and social variables. Therefore, pharmacoepidemiological survey of patients suffering from schizophrenia was carried out to analyze the sociodemographic profile and drug prescribing pattern.

Methods:A prospective observational study was conducted in psychiatry OPD of a tertiary care hospital for nine months. Diagnosis of schizophrenia was made according to DSM IV-TR criteria. Prescriptions were analyzed for socio demographic details, distribution of subsets of disease and psychotropic drugs prescribed.

Results:Amongst 196 cases analyzed, 55.61% were males, 69.9% were below 40 years, 52.04% unmarried, 61.22% belonged to low income group, 82.14% unemployed and 58.16% came from urban locality. Paranoid schizophrenia (79.59%) was the most common diagnosis and a total of 402 psychotropic drugs were prescribed. Average number of psychotropic drugs per prescription was 2.05. Atypical antipsychotics (80.09%) were prescribed more commonly than typical antipsychotics; olanzapine (42.48%) was the commonest antipsychotic drug followed by risperidone (21.68%), haloperidol (19.91%), quetiapine (7.96%), aripiprazole (4.42%) and clozapine (3.54%). As an adjunctive treatment escitalopram, clonazepam and carbamazepine were the commonly prescribed antidepressant, anxiolytic and antimanic agent respectively.

Conclusion:Low socioeconomic status, unemployment, urban locality and living alone are the sociodemographic factors associated with schizophrenia. The treatment pattern observed correlates with the changing trends in the treatment of schizophrenia world over.



Schizophrenia, Epidemiology, Atypical antipsychotics

Full Text:



Piccinelli M, Gomez Homen F. Gender differences in the epidemiology of affective disorders and schizophrenia. In: Piccinelli M, Gomez Homen F, eds. Division of Mental Health and Prevention of Substance Abuse. Geneva: World Health Organization (WHO); 1997: 1-163.

Kirkbride JB, Fearon P. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry. 2006;63(3):250-8.

Kirkbride JB, Morgan C. Neighbourhood-level effects on psychoses: re-examining the role of context. Psychol Med. 2007;37(10):1413-25.

McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67-76.

Messias EL, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am. 2007;30(3):323-38.

Awad AG, Voruganti LN, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics. 1997;11(1):32-47.

Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18(13):877-93.

Picchioni MM, Murray RM. Schizophrenia. Br Med J. 2007;335(7610):91-5.

Malmberg A, Lewis G, David A, Allebeck P. Premorbid adjustment and personality in people with schizophrenia. Br J Psychiatry. 1998;172:308-13.

March D, Hatch SL, Morgan C, Kirkbride JB, Bresnahan M, Fearon P, et al. Psychosis and place. Epidemiol Rev. 2008;30:84-100.

Agerbo E, Byrne M, Eaton WW, Mortensen PB. Marital and labor market status in the long run in schizophrenia. Arch Gen Psychiatry. 2004;61(1):28-33.

Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1-56.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. In: APA, eds. Text Revision. 4th ed. Washington, DC: American Psychiatric Association; 2000: 1-943.

Mccue RE, Waheed R, Urcuo L. Poly pharmacy in patients with schizophrenia. J Clin Psychiatry. 2003;64:984-9.

Trivedi JK, Dhyani M, Yadav VS, Rai SB, Sinha PK. Anti-psychotic drug prescription pattern for schizophrenia: an Indian perspective. Indian J Psychiatry. 2010;52(3):279.

Ramdas S, Kuttichira P, Sumesh TP, Ummer SA. A study of an antipsychotic prescription pattern of patients with schizophrenia in a developing country. Indian J Psychol Med. 2010;32(1):13-6.

McGrath J, Saha S, Welham J. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004;2:13.

Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 2003;60:565-71.

Galani VJ, Patel J, Patel K, Patel D. An epidemiological survey of patients suffering from schizophrenia in Gujarat. Mintage J Pharmaceut Med Sci. 2013;2(1):15-7.

Ali A. Disability in schizophrenia and its relationship with duration of illness and age of onset. Int J Psychosoc Rehab. 2009;14(1):37-41.

Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008;102:1-18.

Lesen E, Anderrson K, Petzoid M, Carlsten A. Socioeconomic determinants of Psychotropic drug utilization among elderly: a national population based cross sectional study. BMC Publ Health. 2010;10:118.

Dohrenwend BP, Levav I, Shrout PE, Schwartz S, Naveh G, Link BG, et al. Socioeconomic status and psychiatric disorders: the causation-selection issue. Science. 1992;255(5047):946-52.

Vassos E, Pedersen CB, Murray RM, Collier DA, Lewis CM. Meta-analysis of the association of urbanicity with schizophrenia. Schizophr Bull. 2012;38(6):1118-23.

Zammit S, Lewis G, Rasbash J, Dalman C, Gustafsson JE, Allebeck P. Individuals, schools, and neighborhood: a multilevel longitudinal study of variation in incidence of psychotic disorders. Arch Gen Psychiatry. 2010;67:914-22.

Banerjee I, Roy B, Sathian B, Banerjee I, Chakraborty PK, Saha A. Socio demographic profile and utilization pattern of antipsychotic drugs among schizophrenic inpatients: a cross sectional study from Western region of Nepal. BMC Psychiatry. 2013; 13:96.

Fahmida A, Wahab MA, Rahman MM. Pattern of psychiatric morbidity among the patients admitted in a private psychiatric clinic. Bangladesh J Med Sci. 2009;8(1-2):23-8.

Dutta SB, Dhasmana DC, Bhardwaj R. Psychotropic drug utilization pattern among schizophrenics. Indian J Psychiatry. 2004;46(4):381-2.

Grover S, Kumar V, Avasthi A, Kulhara P. An audit of first prescription of new patients attending a psychiatry walk-in-clinic in north India. Indian J Pharmacol. 2012;44:319-25.

Sahana DA, Keshava P, Rajeshwari S, Ullal SD, Rathnakar UP, Jaykumar JS. Pattern of psychotropic drug usage in psychiatric illnesses among elderly. J Med Use Devel Countries. 2010;2:3-10.

Kontis D, Theochari E, Kleisas S, Kalogerakou S, Andreopoulou A, Psaras R. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1333-41.

Freeman MP, Stoll AL. Mood stabilizer combination: a review of safety and efficacy. Am J Psychiatry. 1998;155:12-21.